Build your career on Magnet.me
Create a profile and receive smart job recommendations based on your liked jobs.
Summary
Between now and 2029, Novartis aims to launch 3 new molecular entities (NMEs) in the field of rare, life-threatening and underserved renal diseases. The Launch Excellence Manager (LEM) is an early commercial and marketing lead who, together with a cross-functional team, drives the launch strategy for this disease area and priority pipeline assets in the Netherlands. The LEM orchestrates cross-functional work in the Dutch market, with three important priorities: (re-)shaping the market for rare renal diseases, ensuring strong stakeholder relationships, and paving the way for best-in-industry launches of these pipeline NMEs. Must-haves are a strategic and agile mindset, external focus, and proactivity in seizing opportunities that enable access and adoption.
About the Role
Major Accountabilities
Key Performance Indicators (KPIs)
In compliance with local functional business requirements:
Education & Qualifications
University degree in a relevant field, e.g. health sciences, medicine, business, marketing or similar.
Languages
Fluent in Dutch (native tongue) and English (oral and written)
Experiences
Competencies, Skills and Knowledge
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together?
Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
View what's on offer:
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.